AccurKardia Company
AccurKardia delivers automated clinical-grade ECG interpretation software to cardiac monitoring companies, thereby expanding access to the benefits of remote cardiac care to millions of patients worldwide. AccurKardia combines proprietary AI and non-AI based techniques to provide near-real time ECG analytics in the cloud, on device, and at the edge. AccurECG is an FDA cleared, cloud-based, and device agnostic software for fully automated ECG interpretation. It is indicated for adults and is intended to assist cardiac monitoring companies in the analysis of ECGs recorded from holters, event recorders and cardiac telemetry devices. The Company completed Cohort 3 of Mayo Clinic Platform_Accelerate.
Founded Date:
2019-01-01
Last Funding Type:
Seed
Headquarters:
New York, New York, United States
Employee Number:
1-10
Industry:
Analytics, Artificial Intelligence, Health Care, Health Diagnostics, Internet of Things, Machine Learning, Medical, Medical Device, Predictive Analytics, Software
Last Funding Date:
2021
Total Funding:
1470000